Helsinki, Finland
Helsinki, Finland

Time filter

Source Type

The present invention relates to a method for examining a person having the symptoms and/or biomarker indicating an autoimmune disease for the presence of atrophic gastritis. The biomarker combination, which diagnoses atrophic gastritis, acts also as a part of a biomarker panel that helps diagnosis and assessment of autoimmune disease as well. The invention relates also to products used in these methods.


The object of the invention is the use of compounds comprising one or more free sulphhydryl or amino groups for preparing a pharmaceutical composition for locally binding acetaldehyde in saliva, the stomach or the large intestine, and pharmaceutical compositions comprising the said compounds.


Patent
Biohit Oyj | Date: 2013-05-28

The present invention concerns a non-toxic solid pharmaceutical composition for oral administration, containing one or more cysteine compounds from the group of L-cysteine, D-cysteine and N-acetyl cysteine, combined with one or more additional active agents, at least one of which being selected from cystine, glutathione and methionine, the composition further containing one or more pharmaceutical additives. Further, the invention concerns a method for reducing the incidence of severe headaches, particularly migraine and/or cluster headaches.


The present invention relates to non-toxic composition containing, as active compounds, one or more aldehyde-binding compounds, such as L- or D-cysteine, N-acetyl cysteine, and the pharmaceutically acceptable salts thereof, and optionally one or more further active compounds selected from sulphites and xylitol, the composition being used for decreasing the risk of a subject contracting cancer of the stomach, and indirectly of the small intestine and the large intestine. The composition is formulated into a controlled-release formulation consisting of granules contained in a capsule.


The present invention relates to a non-toxic composition containing one or more cysteine compounds selected from L- or D-cysteine, N-acetyl cysteine, and the pharmaceutically acceptable salts thereof, for decreasing the risk of a subject contracting cancer of the stomach, the small intestine and the colon, by locally binding aldehydes present in the stomach, and optionally also separately the aldehydes carried to the small intestine or the colon, or both, whereby the composition is formulated with the help of two or more additives into controlled-release tablets containing at least one additive selected from cationic and gel-forming polymers, which tablets are formed from two or more separate layers with different release profiles, whereby the cysteine compounds are added both into the inner layer(s) and into the tablet material surrounding these.


The present invention concerns products, such as compositions or medical devices, comprising one or more compounds of the Formula I, containing one or more free sulphhydryl groups,


News Article | February 23, 2017
Site: globenewswire.com

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com


News Article | March 1, 2017
Site: globenewswire.com

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com


News Article | February 23, 2017
Site: globenewswire.com

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com


News Article | February 24, 2017
Site: globenewswire.com

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

Loading Biohit Oyj collaborators
Loading Biohit Oyj collaborators